在所有严重血友病A、先前未经治疗的患者(previously unrreated pa-tients，PUP)中，其抑制物的发生率约为25%。近10年来，血友病A患者抑制物发生的几个危险因素被鉴定出来。
基于4个网页-相关网页
结论：卡培他滨和奥沙利铂用于先前未经治疗的食管癌和胃癌患者，效果分别与氟尿嘧啶和顺铂相同。
Conclusions Capecitabine and oxaliplatin are as effective as fluorouracil and cisplatin, respectively, in patients with previously untreated esophagogastric cancer.
先前未经治疗、而对利妥昔单抗诱导缓解有效后接受延长治疗的患者中，8年有45%患者仍无事件发生。
Of previously untreated patients receiving prolonged treatment after responding to rituximab induction, at 8 years 45% were still without event.
应用推荐